Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Asfar S Azmi

Showing results (131-140 of 154) with videos related to

Pageof 16
Sort By:
Clinical and Translational Medicine|December 22, 2023
Molecular analysis of XPO1 inhibitor and gemcitabine-nab-paclitaxel combination in KPC pancreatic cancer mouse modelMd Hafiz Uddin, Mohammad Najeeb Al-Hallak, Husain Yar Khan, et al.
Molecular Cancer Therapeutics|July 13, 2021
PAK4-NAMPT Dual Inhibition Sensitizes Pancreatic Neuroendocrine Tumors to EverolimusGabriel B Mpilla, Md Hafiz Uddin, Mohammed N Al-Hallak, et al.
Biorxiv : the Preprint Server for Biology|April 10, 2023
Anticancer efficacy of KRASG12C inhibitors is potentiated by PAK4 inhibitor KPT9274 in preclinical models of KRASG12C mutant pancreatic and lung cancersHusain Yar Khan, Misako Nagasaka, Amro Aboukameel, et al.
Cancer Letters|September 25, 2024
RCC1 regulation of subcellular protein localization via Ran GTPase drives pancreatic ductal adenocarcinoma growthSahar F Bannoura, Amro Aboukameel, Husain Yar Khan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 31, 2021
Selinexor in Combination with R-CHOP for Frontline Treatment of Non-Hodgkin Lymphoma: Results of a Phase I StudyErlene K Seymour, Husain Yar Khan, Yiwei Li, et al.
Molecular Cancer Therapeutics|September 13, 2023
Anticancer Efficacy of KRASG12C Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of KRASG12C-Mutant Pancreatic and Lung CancersHusain Yar Khan, Misako Nagasaka, Amro Aboukameel, et al.
Lung Cancer (Amsterdam, Netherlands)|September 5, 2021
Impact of XPO1 mutations on survival outcomes in metastatic non-small cell lung cancer (NSCLC)Misako Nagasaka, Mohammad Fahad B Asad, Mohammed Najeeb Al Hallak, et al.
Biorxiv : the Preprint Server for Biology|February 23, 2026
ADT-030, a novel PDE10 inhibitor, demonstrates potent antitumor activity in pancreatic ductal adenocarcinomaDhana Sekhar Reddy Bandi, Ganji Purnachandra Nagaraju, Sujith Sarvesh, et al.
Biorxiv : the Preprint Server for Biology|October 17, 2024
ADT-1004: A First-in-Class, Orally Bioavailable Selective pan-RAS Inhibitor for Pancreatic Ductal AdenocarcinomaDhana Sekhar Reddy Bandi, Ganji Purnachandra Nagaraju, Sujith Sarvesh, et al.
Biorxiv : the Preprint Server for Biology|December 22, 2025
PCNA Inhibition Enhances the Antitumor Activity of KRAS-Targeted Therapies in Pancreatic CancerSahar F Bannoura, Husain Yar Khan, Amro Aboukameel, et al.
Pageof 16

Showing results (131-140 of 154) with videos related to

Sort By:
Pageof 16
Clinical and Translational Medicine|December 22, 2023
Molecular analysis of XPO1 inhibitor and gemcitabine-nab-paclitaxel combination in KPC pancreatic cancer mouse modelMd Hafiz Uddin, Mohammad Najeeb Al-Hallak, Husain Yar Khan, et al.
Molecular Cancer Therapeutics|July 13, 2021
PAK4-NAMPT Dual Inhibition Sensitizes Pancreatic Neuroendocrine Tumors to EverolimusGabriel B Mpilla, Md Hafiz Uddin, Mohammed N Al-Hallak, et al.
Biorxiv : the Preprint Server for Biology|April 10, 2023
Anticancer efficacy of KRASG12C inhibitors is potentiated by PAK4 inhibitor KPT9274 in preclinical models of KRASG12C mutant pancreatic and lung cancersHusain Yar Khan, Misako Nagasaka, Amro Aboukameel, et al.
Cancer Letters|September 25, 2024
RCC1 regulation of subcellular protein localization via Ran GTPase drives pancreatic ductal adenocarcinoma growthSahar F Bannoura, Amro Aboukameel, Husain Yar Khan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 31, 2021
Selinexor in Combination with R-CHOP for Frontline Treatment of Non-Hodgkin Lymphoma: Results of a Phase I StudyErlene K Seymour, Husain Yar Khan, Yiwei Li, et al.
Molecular Cancer Therapeutics|September 13, 2023
Anticancer Efficacy of KRASG12C Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of KRASG12C-Mutant Pancreatic and Lung CancersHusain Yar Khan, Misako Nagasaka, Amro Aboukameel, et al.
Lung Cancer (Amsterdam, Netherlands)|September 5, 2021
Impact of XPO1 mutations on survival outcomes in metastatic non-small cell lung cancer (NSCLC)Misako Nagasaka, Mohammad Fahad B Asad, Mohammed Najeeb Al Hallak, et al.
Biorxiv : the Preprint Server for Biology|February 23, 2026
ADT-030, a novel PDE10 inhibitor, demonstrates potent antitumor activity in pancreatic ductal adenocarcinomaDhana Sekhar Reddy Bandi, Ganji Purnachandra Nagaraju, Sujith Sarvesh, et al.
Biorxiv : the Preprint Server for Biology|October 17, 2024
ADT-1004: A First-in-Class, Orally Bioavailable Selective pan-RAS Inhibitor for Pancreatic Ductal AdenocarcinomaDhana Sekhar Reddy Bandi, Ganji Purnachandra Nagaraju, Sujith Sarvesh, et al.
Biorxiv : the Preprint Server for Biology|December 22, 2025
PCNA Inhibition Enhances the Antitumor Activity of KRAS-Targeted Therapies in Pancreatic CancerSahar F Bannoura, Husain Yar Khan, Amro Aboukameel, et al.
Pageof 16